UROTHELIAL CANCER

This study offers continued access to the cancer drug avelumab (and sometimes other drugs) for people with advanced cancers like lung, ovarian, or bladder cancer who are already seeing benefits from a previous Pfizer-sponsored trial. About 77 participants will be followed for saf…

This study tests a targeted pill (erdafitinib) against standard chemotherapy or immunotherapy in people with advanced bladder cancer that has specific FGFR gene changes. About 629 participants whose cancer worsened after prior treatments will be randomly assigned to receive erdaf…

This phase 2 trial tests a drug called erdafitinib in 239 people with advanced bladder cancer that has certain FGFR gene changes. The drug aims to shrink tumors by blocking signals that help cancer grow. Researchers are checking how well it works and what side effects occur.

This study tests a new drug called raludotatug deruxtecan (R-DXd) in 200 adults with advanced or spreading solid tumors, including certain ovarian, cervical, endometrial, bladder, and kidney cancers. The goal is to see if the drug can shrink tumors or stop them from growing. Part…

This phase 3 study tests whether a combination of two drugs, enfortumab vedotin and pembrolizumab, works better than standard chemotherapy for people with advanced urothelial cancer that has spread. About 886 participants who have not had prior treatment for their advanced cancer…

This early-stage trial is testing a new drug called tuvusertib, given together with either lartesertib or avelumab, in people with advanced solid tumors that have not responded to standard treatments. The main goals are to check safety, find the best dose, and see how the body pr…

This pilot study tested whether adding low-dose radiation (brachytherapy) to standard immunotherapy could help shrink tumors in people with advanced melanoma, kidney cancer, or urothelial cancer. Only 5 participants were enrolled, and the main goal was to see how many responded t…

This Phase 2 trial tests two new immunotherapy drugs, tobemstomig alone or with tiragolumab, against the standard drug atezolizumab. It includes 204 people with advanced bladder cancer who cannot have platinum chemotherapy. The main goal is to check safety and side effects.

This study tested whether two immunotherapy drugs (durvalumab and tremelimumab) work better than standard chemotherapy for people with advanced bladder cancer that has spread (stage IV). Over 1,100 participants received either the drug combination, durvalumab alone, or chemo. The…

This early-stage trial tests a personalized cell therapy called ADP-A2M4CD8 in people with certain cancers that have a specific marker (MAGE-A4). The therapy uses a patient's own immune cells, modified to better attack tumors, and is given alone or with standard immunotherapy dru…

This was a small early-stage trial testing a mix of three drugs (N-803, pembrolizumab, and enfortumab vedotin) for people with advanced bladder cancer who had not yet received any treatment. The goal was to see if the combination was safe and could slow cancer growth. However, th…

This large Phase 3 study tests whether combining two immunotherapy drugs (nivolumab and ipilimumab) or adding nivolumab to standard chemotherapy helps people with advanced bladder cancer live longer than chemotherapy alone. About 1,300 participants with untreated, inoperable or m…

This study tests a two-drug combination (tucatinib and trastuzumab) in people with advanced solid tumors that have HER2 alterations. The goal is to see if the treatment can shrink or control tumors. About 217 participants with various cancers (like lung, uterine, or bile duct) wi…

This study tests a new drug called INCB099280 in 73 people with advanced solid tumors who have not received immunotherapy before. The goal is to see if the drug can shrink tumors and to check for side effects. The study focuses on safety and how well the drug works in the short t…

This early-phase trial is testing a combination of two immunotherapy drugs, naptumomab estafenatox and durvalumab, in 120 people with advanced or metastatic solid tumors like pancreatic, ovarian, and lung cancer. The main goal is to find a safe dose and see how the body reacts. R…

This study tests an experimental drug called BT5528, given alone or with another drug (nivolumab), in people with advanced solid tumors that have high levels of a protein called EphA2. The cancers include ovarian, bladder, lung, breast, head and neck, and stomach cancers. The mai…

This phase 2 study is testing a combination of two drugs, SKB264 and pembrolizumab (Keytruda), in 240 people with certain advanced solid tumors, including cervical, urothelial, ovarian, prostate, and endometrial cancers. The goal is to see if the combination is safe and effective…

This study creates a large registry of people with and without urothelial cancer (bladder, ureter, or renal pelvis cancer) to learn how genes and lifestyle affect risk. Participants provide a saliva sample and fill out questionnaires. The goal is to improve prevention, diagnosis,…